LGCmain
Indian Journal of Pathology and Microbiology
Home About us Instructions Submission Subscribe Advertise Contact e-Alerts Ahead Of Print Login 
Users Online: 1658
Print this page  Email this page Bookmark this page Small font sizeDefault font sizeIncrease font size
IJPM is coming out with a Special issue on "Genitourinary & Gynecological pathology including Breast". Please submit your articles for these issues


 
  Table of Contents    
ORIGINAL ARTICLE  
Year : 2013  |  Volume : 56  |  Issue : 4  |  Page : 388-392
Bacterial profile and patterns of antimicrobial drug resistance in intra-abdominal infections: Current experience in a teaching hospital


1 Department of Microbiology, Vardhman Mahavir Medical College & Safdarjang Hospital, New Delhi, India
2 Department of Surgery, Vardhman Mahavir Medical College & Safdarjang Hospital, New Delhi, India

Click here for correspondence address and email

Date of Web Publication18-Jan-2014
 

   Abstract 

Context: Bacterial isolates from intra-abdominal infections, in particular, peritonitis and their unpredictable antimicrobial resistance patterns, continue to be a matter of concern not only globally but regionally too. Aim: An attempt in the present study was made to study the patterns of drug resistance in bacterial isolates, especially gram negative bacilli in intra-abdominal infections (IAI) in our hospital. Materials and Methods: From 100 cases of peritonitis, identification of isolates was done as per recommended methods. Antimicrobial susceptibility and extended-spectrum beta-lactamase (ESBL) testing were performed following the CLSI guidelines. Results: A total of 133 clinical isolates were obtained, of which 108 were aerobes and 22 anaerobes. Fungal isolates were recovered in only three cases. Escherichia coli (47/108) emerged as the most predominant pathogen followed by Klebsiella spp. (27/108), while Bacteroides fragilis emerged as the predominant anaerobe (12/22). Among coliforms, 61.7% E. coli and 74.1% Klebsiella spp. were ESBL positive. A high level of resistance was observed for beta lactams, ciprofloxacin, amikacin, and ertapenem. Ertapenem resistance (30-41%) seen in coliforms, appears as an important issue. Imipenem, tigecycline, and colistin were the most consistently active agents tested against ESBL producers. Conclusion: Drug resistance continues to be a major concern in isolates from intra-abdominal infections. Treatment with appropriate antibiotics preceded by antimicrobial resistance testing aided by early diagnosis, adequate surgical management, and knowledge of antibiotic - resistant organisms appears effective in reducing morbidity and mortality in IAI cases.

Keywords: Antibiotic resistance, ESBL, gram negative bacilli, intra-abdominal infections.

How to cite this article:
Shree N, Arora BS, Mohil RS, Kasana D, Biswal I. Bacterial profile and patterns of antimicrobial drug resistance in intra-abdominal infections: Current experience in a teaching hospital. Indian J Pathol Microbiol 2013;56:388-92

How to cite this URL:
Shree N, Arora BS, Mohil RS, Kasana D, Biswal I. Bacterial profile and patterns of antimicrobial drug resistance in intra-abdominal infections: Current experience in a teaching hospital. Indian J Pathol Microbiol [serial online] 2013 [cited 2019 Dec 7];56:388-92. Available from: http://www.ijpmonline.org/text.asp?2013/56/4/388/125321



   Introduction Top


Generalized peritonitis due to intra-abdominal infections (IAIs), despite advances in surgical techniques, comprise more than 25% of emergency operations in our hospitals. [1] Decline in morbidity and mortality in IAI is a welcome observation in Indian scenario. [1] Knowing the prevalent pattern of antimicrobial resistance is an important issue especially when gram negative isolates continue to exhibit rampant resistance to various currently in use antimicrobial agents. [2] Therefore, empirical selection of the right kind of anti-microbial therapy is significant in reducing morbidity and mortality. In Indian context, data especially antimicrobial resistance status is still scarce for this very common problem.


   Materials and Methods Top


A total of 100 cases of intra-abdominal sepsis were studied in department of Microbiology and General Surgery of our hospital from November, 2010 to January, 2012 (15 months). A total of 125 clinical specimens (Pus/exudates, 0.5 ml minimum and blood, 10 ml) from 100 cases of intra-abdominal sepsis were collected aseptically in Robertson Cooked Meat (RCM) medium from patients presenting with clinical picture of acute intra-abdominal sepsis and subjected to culture and isolation for clinically significant isolates as per the criteria laid down in Mackie and McCartney, 14th edition [3] and Wadsworth manual of anaerobic bacteriology. [4] The majority of specimens were obtained during surgery, though some specimens were also taken post-operatively from cases of burst abdomen. The specimens were processed for isolation of aerobic and anaerobic bacteria by using standard microbiological techniques and their antimicrobial susceptibility was determined by using Kirby-Bauer disk diffusion technique recommended by Clinical & Laboratory Standards Institute (CLSI), 2010 guidelines. [5] For antimicrobial susceptibility testing quality control was performed using  Escherichia More Details coli ATCC 25922; Klebsiella pneumoniae 700603 extended - spectrum beta-lactamase (ESBL)- positive control strain), and Pseudomonas aeruginosa ATCC 25843 strains.

Testing of ESBL

ESBL detection was done by phenotypic method as per CLSI (2010) recommended clavulanate combined disk and double disk synergy test using cefotaxime (30 μg), ceftazidime (30 μg) and combination of cefotaxime (30 μg)-/ceftazidime (30 μg) and clavulanic acid (10 μg). The zone diameter given by the disks with clavulanate was ≥5 mm or larger than those without the inhibitor if an ESBL was produced.

Statistical analysis

The results were tabulated and analyzed by SPSS 16 software using the chi-square (χ2 )-tests. A 'P' value of less than 0.05 was taken as significant. The study was approved by Ethical Committee of our hospital.


   Results Top


A total of 108 strains of aerobic bacteria and 22 strains of anaerobic bacteria (either as sole pathogen or in association with other organisms) were isolated during the present study. Three Candida spp. were also isolated. The 92 aerobic Gram negative bacilli (GNB) isolates comprised of 47 (43.5%) E. coli, Klebsiella spp. 27 (25.4%), Acinetobacter spp. 08 (7.4%), P. aeruginosa 06 (5.5%), Enterobacter spp 02 (1.8%), Citrobacter spp. 01 (0.9%) and Proteus vulgaris 01 (0.9%). The most commonly isolated organism was E. coli, of which 61.7% of the isolates (n = 29) were ESBL positive. Among Klebsiella isolates, 74.9 % (n = 20) were ESBL positive. [Table 1] illustrates the distribution of aerobes and anaerobes (including Candida spp.) and their antimicrobial resistance pattern.
Table 1: Resistance rates (%) of various gram negati ve non-duplicate clinical isolates

Click here to view


The antimicrobial resistance levels of E. coli, and Klebsiella spp. to the carbapenems ranged from 29% to 41% (ertapenem), 14% to 15% (meropenem), and nil toward imipenem. Imipenem, tigecycline, and colistin remained the most consistently active against all gram negative pathogens. Susceptibility to other commonly used antibiotics including cephalosporins, fluoroquinolones, aminoglycosides, and carbapenems also showed a decline. Resistance levels were higher for the ESBL-producing organisms [Table 2]. A high level of resistance among gram negative organisms to third generation cephalosporin antibiotics as well as β lactam/β lactamase inhibitors is also evident [Figure 1]. Resistance rates for E. coli strains were as high as 78.7% for ciprofloxacin, 72.3% for cefotaxime, 25.5% for amikacin, 46.8% for netilmicin, 28% for piperacillin/tazobactam combination, 32% for cefoperazone/sulbactam combination, 30% and 15% for ertapenem and meropenem, respectively.
Table 2: Frequency of ESBL* producti on in  Escherichia coli Scientific Name Search siella spp. in IAI

Click here to view
Figure 1: Anti bioti c resistance in Escherichia coli & Klebsiella spp

Click here to view


Sensitivity patterns of Klebsiella spp. also revealed low susceptibility for various antimicrobials with a resistance rate of 81.5% for cefotaxime, 66.7% for ciprofloxacin, 41%, 48%, 47%, 37% & 41% & 15% respectively for amikacin, netilmicin, piperacillin/tazobactam combination, cefoperazone/sulbactam combination and ertapenem & meropenem. Overall, imipenem, tigecycline and colistin appeared to be the most effective (100 %) against the majority of gram negative isolates.

In P. aeruginosa, a resistance rate of 66.67% (n = 04) and 50% (n = 03) was observed for ciprofloxacin and netilmicin respectively, whereas 33.33% (n = 02) resistance was observed for amikacin and meropenem. Resistance toward aztreonam, imipenem was not seen, while colistin was, in vitro, highly effective. Eight strains of Acinetobacter spp. isolates revealed resistance rate of 62.5%, 50%, 37.5%, 25%, and 12.5% for netilmicin, amikacin, meropenem, ciprofloxacin, and piperacillin/tazobactam in a decreasing order of resistance, respectively. Nil resistance was seen for imipenem and colistin. For gram positive cocci, a high level of resistance toward penicillin, ciprofloxacin, gentamicin in staphylococcal and enterococcal spp. was observed; however, these isolates were fully susceptible to vancomycin.


   Discussion Top


In accord with the several global and regional reports, our study also revealed E. coli as the most frequent pathogen associated with IAI. [6],[7] As also reported by others, in addition to E. coli, Klebsiella spp, P. aeruginosa, and Acinetobacter spp. were among other gram negative isolates. [8],[9],[10] In a study by Stephen P. Hawser in 2008, from several hospitals in India (SMART study), the most frequently isolated pathogens were E. coli (62.7 %), K. pneumoniae (16.7 %), and P. aeruginosa (5.3 %) while in another similar study by Maria Virginia Villegas et al. from 10 Latin American countries, E. coli and K. pneumoniae were the most commonly isolated organisms from such IAI. [9]

The prevalence of multi-drug-resistant gram negative bacilli, especially ESBL producers, has increased worldwide with marked regional variations of their distribution. [8],[9],[10] In our study, ESBL producers were seen to the extent of 61.70% in E. coli and 74.07% in Klebsiella spp. Stephen P. Hawser et al. (2008) reported 67 % and 55 % ESBL production respectively in E. coli and K. pneumoniae isolates in a SMART study from India. Apart from SMART global surveillance programme, several other local reports have also described variable ESBL rates in India, for example, Aggarwal et al. (2008) [11] reported ESBL rates as 22 % in E. coli and Klebsiella pneumonia in Pune, while Sinha et al. (2008) [12] showed the rates as high as 64.8 % in Jaipur. Frequency of ESBL producers as low as 26% and 35% respectively in E. coli and Klebsiella spp. has been observed in Latin American countries, [9] while the same has been reported as 36.8% and 26.3% in E. coli and Klebsiella spp. in Asia-Pacific region. [7] Variations in ESBL rates as documented by these studies reinforce the prevalence of regional variations and emphasize the need for frequent studies.

For antimicrobial resistance, interestingly, in E. coli, resistance was as high as 78.7% for ciprofloxacin, 72.3% for cefotaxime but it was relatively low for piperacillin/tazobactam (28%) and cefoperazone/sulbactam (32%) combinations. Among aminoglycosides, resistance levels of 25.5% for amikacin, 46.8% for netilmicin, while 30% and 15% for carbapenems i.e. ertapenem and meropenem respectively were evident. The resistance level for ciprofloxacin and aminoglycosides were comparatively higher than that reported by other investigators such as by Sepehri G, Goldstein and Syndman and Paterson et al. These investigators reported such resistance in the range 3-23%. [10],[13],[14]

Klebsiella spp. was relatively more resistant to commonly used antimicrobial agents with resistance levels as high as 81.5% for cefotaxime and 66.7% for ciprofloxacin. For other antimicrobials, resistance levels as 41% for amikacin, 48% for netilmicin, 47% for piperacillin/tazobactam combination, 37% for cefoperazone/sulbactam, & 41% & 15% respectively for ertapenem & meropenem were observed in that decreasing order. Our results are in accord with several other studies that revealed an increase in resistance in Klebsiella spp. from different regions of the world, namely Chen et al., Hauser et al., Sepehri and Villages et al.[7],[9],[10]

Imipenem, tigecycline, and colistin appeared as the most active drugs against E. coli and Klebsiella spp. (100% susceptible) which again tallies with the results of other investigators, namely Villages et al., Hauser et al., Chaudhuri et al.[9],[10],[15],[16],[17],[18],[19] Genotypic resistance marker analyses are limitations of our study but clearly increase in resistance, whether due mainly to ESBL production or hitherto other yet unclear mechanisms with tagged clinical impact remain a potential threat in treating such infections. [9] Plasmids responsible for ESBL production carrying genes encoding resistance to several other structural drug classes' especially aminoglycosides and fluoroquinolones have been identified making options of treating such infections difficult and extremely limited. In addition, fast emerging reports of carbapenem-resistant isolates are making situation still worse. [14]

P. aeruginosa and Acinetobacter spp. are other major nosocomial pathogens which display remarkable properties of resistance to many antibiotics; therefore, their isolation is an important cause of concern. [20],[21],[22] Six strains of P. aeruginosa showed high resistance level of 66.67% (n = 04) and 50% (n = 03) for ciprofloxacin and netilmicin respectively, whereas 33.33% (n = 02) resistance was observed for amikacin and meropenem separately. Resistance toward aztreonam, imipenem was not seen, while colistin was highly effective. Eight strains of Acinetobacter spp. isolated revealed resistance levels of 62.5%, 50%, 37.5%, 25%, and 12.5% for netilmicin, amikacin, meropenem, ciprofloxacin, and piperacillin/tazobactam respectively in that decreasing order but resistance for imipenem and colistin was not evident. It is comparatively lesser when compared with other studies. [20],[21],[22] Interestingly again, a satisfactory coverage with piperacillin/tazobactam combination and imipenem against these isolates has been reported by several other workers. [20],[21],[22] The present study did not include screening of Amp C beta lactamases and metallo beta lactamases (MBLs) production which is an important limitation of our study. Among gram positive isolates, the number of isolates is too less to make any definitive conclusions. Only 12 strains of Staphylococcus aureus isolated in the present study revealed resistance level of 50% (n = 06) toward erythromycin, clindamycin, and ciprofloxacin (50%). In Staphylococci, emergence of methicillin-resistant Staphylococcus aureus Scientific Name Search  (MRSA) in hospital settings and therapeutic challenges it poses are well recognized. The presence of MRSA narrows down the therapeutic options to treat these infections. Of the 12 Staphylococcal isolates five strains (42%) were MRSA. Among these - 3 (60%) were sensitive to vancomycin; 1 (20%) to ciprofloxacin and vancomycin separately, and 1 (20%) to gentamicin and vancomycin separately revealing the limited options for the alternative antimicrobial agents. All five strains of S. aureus were sensitive to vancomycin (100%). Rising levels of clindamycin resistance 6/12 (50%) in Staphylococcus aureus as seen in the present study appears an unhealthy sign when compared to low levels of resistance as reported in previous studies. [23],[24],[25] In Enterococci, an increased resistance to various antimicrobial agents was observed as also reported in other studies. [26],[27] Of the only 4 strains of Enterococci isolated, 3/4 (75%) were resistant to penicillin, 2/4 (50%) to ciprofloxacin and chloramphenicol, and 1/4 (25%) to gentamicin. However, all these four strains were sensitive to vancomycin (100%). The resistance level seen in our study for S. aureus and Enterococci is comparatively higher than that reported by Montravers et al.[20] B. fragilis is among the most common anaerobic isolate from IAIs. [13],[28] Of the 12 strains isolated, antimicrobial susceptibility of 10 strains revealed that all strains were sensitive to metronidazole, ertapenem, and meropenem, and to combination of piperacillin and tazobactam. All strains, except one, were sensitive to clindamycin and augmentin. Metronidazole, ertapenem, meropenem, and piperacillin/tazobactam combination were found 100% effective. All these antibiotics can also be used, if required, as an alternative to metronidazole for treating anaerobic infections. The universal bactericidal activity of metronidazole against B. fragilis and other anaerobes is well documented albeit rare reports of metronidazole resistance. Excellent activity against Bacteroides fragilis of several antimicrobials like metronidazole, ampicillin/sulbactam, piperacillin/tazobactam, ertapenem, meropenen imipenem along with good to moderate activity of cefoxitin is indeed well documented. [13],[28]


   Conclusion Top


The study emphasizes need for antimicrobial susceptibility testing of clinically significant isolates not only as a routine procedure but also on periodic basis, especially when no definitive resistance or susceptibility patterns are available in a given geographic location.


   Acknowledgement Top


We are thankful to Dr.Monorama Deb, M.D., Professor and Head (Microbiology Department), and technical staff, especially Miss. Lata Kalra - Department of Microbiology, VMMC & Safdarjang hospital, New Delhi for their technical cooperation.

 
   References Top

1.Agarwal N, Saha S, Srivastava A, Chumber S, Dhar A, Garg S. Peritonitis: 10 years' experience in a single surgical unit. Trop Gastroenterol 2007;28:117-20.   Back to cited text no. 1
    
2.Hawser SP, Badal RE, Bouchillon SK, Hoban DJ; SMART India Working Group. Antibiotic Susceptibility of Intra Abdominal Infection isolates from Indian Hospitals during 2008. J Med Microbiol 2010;59:1050-4.  Back to cited text no. 2
    
3.Collee JG, Miles RS, Watt B. Mackie and McCartney Practical Medical Microbiology. Collee JG, Fraser AG, Marmion BP, Simmons A. Tests for identification of bacteria. 14 th ed. USA: 1996; Elsevier. p. 131-49.  Back to cited text no. 3
    
4.Somer HR, Summanen P, Citron DM, Baron EJ, Wexler HM, Finegold SM. Wadsworth-KTL Anaerobic bacteriology Manual. 6 th ed. Belmont, California 2002; Star.  Back to cited text no. 4
    
5.Clinical Laboratory Standards Institute; Performance standards for antimicrobial susceptibility testing. 20 th Informational Supplement: 2010.  Back to cited text no. 5
    
6.Rossi F, Baquero F, Hsueh PR, Paterson DL, Bochicchio GV, Snyder TA, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 Study for monitoring antimicrobial resistance trends (SMART). J Antimicrob Chemother 2006;58:205-10.   Back to cited text no. 6
    
7.Chen YH, Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect 2011;62:280-91.  Back to cited text no. 7
    
8.Sepehri G, Nejad HZ, Sepehri E, Razban S. Bacterial profile and antimicrobial resistance to commonly used antimicrobials in intra-abdominal infections in two Teaching Hospitals. Am J Applied Sci 2010;7:38-43.  Back to cited text no. 8
    
9.Villegas MV, Blanco MG, Sifuentes-Osornio J, Rossi F. Increasing prevalence of extended-spectrum-beta lactamase among gram-negativebacilli in latin america - 2008 update from the study for monitoring antimicrobial resistance trends (smart). Braz J Infect Dis 2011;15:34-9.   Back to cited text no. 9
    
10.Hauser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, Paterson DL. Emergence of high levels of ESBL producing gram negative bacilli in the asia pacific region: Data from the study for monitoring antimicrobial resistance trends( SMART) programme, 2007. Antimicrob Agents Chemother 2009;53:3280-4.  Back to cited text no. 10
    
11.Agrawal P, Ghosh AN, Kumar S, Basu B, Kapila K. Prevalence of extended-spectrum-beta-lactamases among Escherichia coli and Klebsiella pneumoniae isolates in a tertiary care hospital. Indian J Pathol Microbiol 2008;51:139-42.  Back to cited text no. 11
[PUBMED]  Medknow Journal  
12.Sinha P, Sharma R, Rishi S, Sharma R, Sood S, Pathak D. Prevalence of extended spectrum beta-lactamases and AmpC beta-lactamase producers among Escherichia coli isolates in a tertiary care hospital in Jaipur. Indian J Pathol Microbiol 2008;51:367-9.  Back to cited text no. 12
[PUBMED]  Medknow Journal  
13.Goldstein EJ, Syndman DR. Intra-abdominal infections: Review of the bacteriology, antimicrobial susceptibility and the role of etrapenam in their therapy. J Antimicrob Chemother 2004;53:29-36.  Back to cited text no. 13
    
14.Paterson DL, Rossi F, Baquero F, Hsuehand PR, Woods GL, Satishchandran V, et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2003 Study for monitoring antimicrobial resistance trends (SMART). J Antimicrob Chemother 2005;55:965-73.  Back to cited text no. 14
    
15.Chaudhuri BN, Rodrigues C, Balaji V, Iyer R, Sekar U, Wattal C, et al. Incidence of ESBL producers amongst Gram-negative bacilli isolated from intra-abdominal infections across India (based on SMART study, 2007 data). J Assoc Physicians India 2011;59:287-92.  Back to cited text no. 15
    
16.Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis 2005;41 Suppl 5:S354-67.  Back to cited text no. 16
    
17.Bradford PA, Weaver-Sands DT, Patersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infection and complicated abdominal infections. Clin Infect Dis 2005;41 Suppl 5:S315-32.  Back to cited text no. 17
    
18.Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 2005;25:11-25.  Back to cited text no. 18
    
19.Stein A, Raoult D. Colistin: An antimicrobial for the 21st century? Clin Infect Dis 2002;35:901-2.  Back to cited text no. 19
    
20.Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, et al. Clinical and microbiological profiles of community acquired and nosocomial intra-abdominal infections: Result of the french prospective, observational EBIIA study. J Antimicrob Chemother 2009;63:785-94.  Back to cited text no. 20
    
21.Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of pseudomonas aeruginosa infections. Drugs 2007;67:351-68.   Back to cited text no. 21
    
22.Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multi-drug resistant pseudomonas aeruginosa: Epidemiology and treatment options. Pharmacotherapy 2005;25:1353-64.  Back to cited text no. 22
    
23.Brook I. Microboilogy and management of peritonsillar, retropharyngeal and parapharyngeal abscesses. J Oral MaxillofacSurg 2004;62:1545-50.  Back to cited text no. 23
    
24.Meher R, Jain A, Sabharwal A, Gupta B, Singh I, Agarwal AK. Deep neck abscess: A prospective study of 54 cases. J Laryngol Otol 2005;119:299-302.  Back to cited text no. 24
    
25.Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, et al. Comparison of community- and health-care associated methicillin resistant Staphylococcus aureus infection. JAMA 2003;290:2976-84.  Back to cited text no. 25
    
26.Burnett RJ, Haverstock DC, Dellinger EP, Reinhart HH, Bohnen JM, Rotstein OD, et al. Definition of the role of enterococcus in intraabdominal infection: Analysis of a prospective randomized trial. Surgery 1995;118:716-21.  Back to cited text no. 26
    
27.Sood S, Malhotra M, Das BK, Kapil A. Enterococcal infections & antimicrobial resistance. Indian J Med Res 2008;128:111-21.  Back to cited text no. 27
[PUBMED]  Medknow Journal  
28.Lee Y, Park Y, Kim MS, Yong D, Jeong SH, Lee K, et al. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. Antimicrob Agents Chemother 2010;54:3993-7.  Back to cited text no. 28
    

Top
Correspondence Address:
Balvinder S Arora
Departments of Microbiology, Vardhman Mahavir Medical College & Safdarjang Hospital, Room No - 507, 5th Floor, College Building, New Delhi - 110 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0377-4929.125321

Rights and Permissions


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2]

This article has been cited by
1 Treating Surgical Infections in Low- and Middle-Income Countries: Source Control, Then What?
Jennifer Rickard
Surgical Infections. 2019; 20(3): 192
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
    Materials and Me...
   Results
   Discussion
   Conclusion
   Acknowledgement
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed6427    
    Printed106    
    Emailed1    
    PDF Downloaded328    
    Comments [Add]    
    Cited by others 1    

Recommend this journal